Efficacy and Safety of Rituximab Versus Inebilizumab in Patients With Neuromyelitis Optica Spectrum Disorder: A Dual-Center, Real-World Cohort Study.

Key Points

• This study aims to compare the efficacy and safety of rituximab and inebilizumab in patients with neuromyelitis optica spectrum disorder.
• Real-world cohort study
• 276 patients analyzed
• Efficacy measured over medium term
• Safety profiles evaluated during treatment
• Rituximab and inebilizumab showed comparable efficacy
• Rituximab group had a higher incidence of infusion-related reactions
• Differing safety profiles were observed between the two treatments